7.59
price down icon5.60%   -0.45
 
loading
前日終値:
$8.04
開ける:
$8.1
24時間の取引高:
3.23M
Relative Volume:
1.91
時価総額:
$521.98M
収益:
$161.10M
当期純損益:
$-308.60M
株価収益率:
-1.6253
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
-13.26%
1か月 パフォーマンス:
-56.03%
6か月 パフォーマンス:
-69.32%
1年 パフォーマンス:
-81.61%
1日の値動き範囲:
Value
$7.53
$8.13
1週間の範囲:
Value
$7.53
$8.86
52週間の値動き範囲:
Value
$7.53
$41.34

Arvinas Inc Stock (ARVN) Company Profile

Name
名前
Arvinas Inc
Name
セクター
Healthcare (1166)
Name
電話
203-535-1456
Name
住所
395 WINCHESTER AVE, NEW HAVEN, CT
Name
職員
430
Name
Twitter
@ArvinasInc
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
ARVN's Discussions on Twitter

ARVN を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ARVN
Arvinas Inc
7.59 521.98M 161.10M -308.60M -259.90M -4.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-13 ダウングレード Goldman Buy → Neutral
2025-03-12 ダウングレード Wedbush Outperform → Neutral
2025-03-11 ダウングレード Oppenheimer Outperform → Perform
2024-12-10 開始されました BTIG Research Buy
2024-11-18 開始されました Stephens Overweight
2024-02-28 繰り返されました Oppenheimer Outperform
2024-02-14 ダウングレード Citigroup Buy → Neutral
2024-02-01 開始されました Goldman Buy
2023-12-19 アップグレード Wells Fargo Equal Weight → Overweight
2023-12-06 アップグレード Jefferies Hold → Buy
2023-11-20 アップグレード Guggenheim Neutral → Buy
2023-10-23 アップグレード Wedbush Neutral → Outperform
2023-06-26 再開されました Oppenheimer Outperform
2023-01-12 ダウングレード Guggenheim Buy → Neutral
2023-01-03 ダウングレード Wells Fargo Overweight → Equal Weight
2022-09-09 開始されました Barclays Overweight
2022-06-21 開始されました Jefferies Hold
2022-05-09 ダウングレード Wedbush Outperform → Neutral
2022-04-28 開始されました Credit Suisse Outperform
2022-04-06 開始されました Morgan Stanley Equal-Weight
2022-02-11 再開されました BMO Capital Markets Outperform
2022-02-10 開始されました Wells Fargo Overweight
2022-01-19 開始されました Goldman Buy
2021-12-07 開始されました Cowen Outperform
2021-10-14 開始されました SVB Leerink Outperform
2021-09-30 開始されました Stifel Buy
2021-09-09 開始されました BofA Securities Buy
2021-05-21 開始されました UBS Buy
2021-04-21 開始されました Truist Buy
2021-03-31 開始されました BMO Capital Markets Outperform
2020-12-14 アップグレード Oppenheimer Perform → Outperform
2020-06-01 アップグレード Citigroup Neutral → Buy
2020-05-12 開始されました Oppenheimer Perform
2019-12-19 開始されました H.C. Wainwright Buy
2019-11-25 開始されました Guggenheim Buy
2019-10-24 アップグレード Goldman Neutral → Buy
2019-09-25 開始されました Wedbush Outperform
2019-09-12 開始されました BMO Capital Markets Outperform
2019-08-06 開始されました Cantor Fitzgerald Overweight
2019-06-05 ダウングレード Citigroup Buy → Neutral
2019-04-12 開始されました Evercore ISI Outperform
2018-10-22 開始されました Citigroup Buy
2018-10-22 開始されました Goldman Neutral
2018-10-22 開始されました Piper Jaffray Overweight
すべてを表示

Arvinas Inc (ARVN) 最新ニュース

pulisher
Mar 28, 2025

Arvinas (NASDAQ:ARVN) Reaches New 52-Week LowHere's What Happened - MarketBeat

Mar 28, 2025
pulisher
Mar 28, 2025

Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by BIT Capital GmbH - MarketBeat

Mar 28, 2025
pulisher
Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - StockTitan

Mar 27, 2025
pulisher
Mar 26, 2025

Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat

Mar 23, 2025
pulisher
Mar 21, 2025

Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat

Mar 21, 2025
pulisher
Mar 20, 2025

Wedbush Has Positive Outlook for Arvinas Q1 Earnings - MarketBeat

Mar 20, 2025
pulisher
Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Down -54.85% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 19, 2025
pulisher
Mar 19, 2025

Arvinas chief medical officer sells $74,372 in common stock - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Arvinas Chief Medical Officer Sells Shares to Cover Tax Obligations - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 19, 2025
pulisher
Mar 18, 2025

Is Arvinas, Inc. (ARVN) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Arvinas (NASDAQ:ARVN) Price Target Cut to $12.00 by Analysts at Morgan Stanley - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Guggenheim Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat

Mar 17, 2025
pulisher
Mar 17, 2025

Arvinas (NASDAQ:ARVN) Rating Lowered to Neutral at The Goldman Sachs Group - MarketBeat

Mar 17, 2025
pulisher
Mar 16, 2025

Arvinas (NASDAQ:ARVN) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Arvinas (NASDAQ:ARVN) Given New $28.00 Price Target at Bank of America - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Arvinas (NASDAQ:ARVN) Hits New 1-Year LowHere's What Happened - MarketBeat

Mar 16, 2025
pulisher
Mar 15, 2025

Oppenheimer Downgrades Arvinas (NASDAQ:ARVN) to Market Perform - MarketBeat

Mar 15, 2025
pulisher
Mar 15, 2025

Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat

Mar 15, 2025
pulisher
Mar 14, 2025

Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J - Yahoo Finance

Mar 14, 2025
pulisher
Mar 14, 2025

Arvinas: Veritac-2 ITT Failure Confirms Limited Prospects - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

Arvinas’s SWOT analysis: biotech stock faces pivotal trials amid competition By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Bank of America Lowers Arvinas (NASDAQ:ARVN) Price Target to $28.00 - Defense World

Mar 14, 2025
pulisher
Mar 14, 2025

Arvinas (NASDAQ:ARVN) Stock Rating Lowered by Wedbush - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Arvinas Plunges 40% After Pfizer-Partnered Drug Disappoints - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Arvinas Inc Reports Q4 2024 EPS of -$0.63, Beating Estimates, Re - GuruFocus.com

Mar 13, 2025

Arvinas Inc (ARVN) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):